STOCK TITAN

[Form 4] Thermo Fisher Scientific, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Frederick M. Lowery, Executive Vice President of Thermo Fisher Scientific (TMO), reported multiple disposals of common stock on 08/28/2025 at a price of $489.74 per share. The Form 4 shows four separate disposition entries totaling 667.718 shares disposed (175.028 + 187.116 + 186.632 + 118.942) and remaining direct beneficial ownership reported in fractional amounts (14,860.0624; 14,672.9464; 14,486.3144; 14,367.3724 across lines). The filing also reports indirect holdings of 1,174.88 shares through a 401(k) plan and 5.036 shares via a limited liability company, with a disclaimer of beneficial ownership for the LLC position.

Frederick M. Lowery, Executive Vice President di Thermo Fisher Scientific (TMO), ha effettuato diverse cessioni di azioni ordinarie il 28/08/2025 al prezzo di 489,74 USD per azione. Il modulo Form 4 riporta quattro operazioni distinte per un totale di 667,718 azioni cedute (175,028 + 187,116 + 186,632 + 118,942) e la titolarità diretta residua indicata in valori frazionari (14,860.0624; 14,672.9464; 14,486.3144; 14,367.3724 sulle varie righe). La dichiarazione segnala inoltre partecipazioni indirette per 1,174.88 azioni tramite un piano 401(k) e 5.036 azioni attraverso una società a responsabilità limitata, specificando una rinuncia alla titolarità effettiva per la posizione nella LLC.

Frederick M. Lowery, vicepresidente ejecutivo de Thermo Fisher Scientific (TMO), reportó múltiples disposiciones de acciones ordinarias el 28/08/2025 a un precio de 489,74 USD por acción. El Formulario 4 muestra cuatro entradas de disposición separadas que suman 667,718 acciones desinvertidas (175,028 + 187,116 + 186,632 + 118,942) y la propiedad directa restante informada en cantidades fraccionarias (14,860.0624; 14,672.9464; 14,486.3144; 14,367.3724 en las distintas líneas). La presentación también informa participaciones indirectas de 1,174.88 acciones a través de un plan 401(k) y 5.036 acciones vía una sociedad de responsabilidad limitada, con una renuncia de propiedad beneficiaria sobre la posición en la LLC.

Frederick M. Lowery, Thermo Fisher Scientific(TMO) 전무이사는 2025-08-28에 보통주를 주당 489.74달러에 여러 차례 처분했습니다. Form 4에는 각각 175.028, 187.116, 186.632, 118.942주로 총 667.718주를 처분한 네 건의 별도 처분 항목과, 각 항목별로 잔여 직접 보유 주식이 소수점 단위로 보고되어 있습니다(14,860.0624; 14,672.9464; 14,486.3144; 14,367.3724). 제출서에는 또한 401(k) 계획을 통한 간접 보유 1,174.88주와 유한책임회사(LLC)를 통한 5.036주의 간접 보유가 기재되어 있으며, LLC 지분에 대해서는 수익적 소유권을 부인하고 있습니다.

Frederick M. Lowery, vice-président exécutif de Thermo Fisher Scientific (TMO), a réalisé plusieurs cessions d'actions ordinaires le 28/08/2025 au prix de 489,74 USD par action. Le formulaire 4 indique quatre écritures de cession distinctes totalisant 667,718 actions cédées (175,028 + 187,116 + 186,632 + 118,942) et la détention directe restante signalée en montants fractionnaires (14,860.0624; 14,672.9464; 14,486.3144; 14,367.3724 selon les lignes). Le dépôt signale également des participations indirectes de 1,174.88 actions via un plan 401(k) et de 5.036 actions via une société à responsabilité limitée, avec une déclinaison de propriété bénéficiaire pour la position détenue par la LLC.

Frederick M. Lowery, Executive Vice President von Thermo Fisher Scientific (TMO), meldete mehrere Veräußerungen von Stammaktien am 28.08.2025 zu einem Kurs von 489,74 USD je Aktie. Das Formular 4 weist vier separate Veräußerungsposten aus, die insgesamt 667,718 veräußerte Aktien ergeben (175,028 + 187,116 + 186,632 + 118,942), und den verbleibenden direkten Besitz in Bruchteilen (14,860.0624; 14,672.9464; 14,486.3144; 14,367.3724 in den jeweiligen Zeilen). Die Meldung nennt außerdem indirekte Beteiligungen von 1,174.88 Aktien über einen 401(k)-Plan und 5.036 Aktien über eine Limited Liability Company, wobei für die LLC-Position das wirtschaftliche Eigentum verneint wird.

Positive
  • Continued equity ownership shown via a TMO 401(k) holding of 1,174.88 shares
  • Disclosure of indirect ownership through a limited liability company (5.036 shares) with a clear disclaimer
Negative
  • Insider disposed of 667.718 shares across four reported transactions on 08/28/2025
  • Multiple disposal entries reduced direct share counts as shown by the reported post-transaction ownership lines

Insights

TL;DR: Multiple insider stock dispositions occurred on 08/28/2025 at $489.74, while the reporting person retains both direct and indirect holdings.

The report documents four discrete disposition transactions totaling 667.718 shares sold at $489.74 each. Post-transaction direct ownership is recorded on multiple lines as fractional share totals. Additionally, 1,174.88 shares are held in a TMO 401(k) and 5.036 shares are held indirectly via an LLC, with a disclaimer of beneficial ownership for the LLC stake. From an investor-data perspective, these are standard insider liquidity transactions without accompanying company operational or financial metrics in the filing.

TL;DR: The Form 4 discloses routine insider dispositions and stated indirect holdings; no governance events or role changes are reported.

The form indicates the reporting person is an Executive Vice President and lists multiple dispositions executed the same day under transaction code F. The filing clarifies indirect ownership categories (401(k) and an LLC) and includes a standard disclaimer regarding the LLC interest. There are no amendments, officer title changes, or joint filers noted. This disclosure meets Section 16 reporting requirements but does not signal governance actions.

Frederick M. Lowery, Executive Vice President di Thermo Fisher Scientific (TMO), ha effettuato diverse cessioni di azioni ordinarie il 28/08/2025 al prezzo di 489,74 USD per azione. Il modulo Form 4 riporta quattro operazioni distinte per un totale di 667,718 azioni cedute (175,028 + 187,116 + 186,632 + 118,942) e la titolarità diretta residua indicata in valori frazionari (14,860.0624; 14,672.9464; 14,486.3144; 14,367.3724 sulle varie righe). La dichiarazione segnala inoltre partecipazioni indirette per 1,174.88 azioni tramite un piano 401(k) e 5.036 azioni attraverso una società a responsabilità limitata, specificando una rinuncia alla titolarità effettiva per la posizione nella LLC.

Frederick M. Lowery, vicepresidente ejecutivo de Thermo Fisher Scientific (TMO), reportó múltiples disposiciones de acciones ordinarias el 28/08/2025 a un precio de 489,74 USD por acción. El Formulario 4 muestra cuatro entradas de disposición separadas que suman 667,718 acciones desinvertidas (175,028 + 187,116 + 186,632 + 118,942) y la propiedad directa restante informada en cantidades fraccionarias (14,860.0624; 14,672.9464; 14,486.3144; 14,367.3724 en las distintas líneas). La presentación también informa participaciones indirectas de 1,174.88 acciones a través de un plan 401(k) y 5.036 acciones vía una sociedad de responsabilidad limitada, con una renuncia de propiedad beneficiaria sobre la posición en la LLC.

Frederick M. Lowery, Thermo Fisher Scientific(TMO) 전무이사는 2025-08-28에 보통주를 주당 489.74달러에 여러 차례 처분했습니다. Form 4에는 각각 175.028, 187.116, 186.632, 118.942주로 총 667.718주를 처분한 네 건의 별도 처분 항목과, 각 항목별로 잔여 직접 보유 주식이 소수점 단위로 보고되어 있습니다(14,860.0624; 14,672.9464; 14,486.3144; 14,367.3724). 제출서에는 또한 401(k) 계획을 통한 간접 보유 1,174.88주와 유한책임회사(LLC)를 통한 5.036주의 간접 보유가 기재되어 있으며, LLC 지분에 대해서는 수익적 소유권을 부인하고 있습니다.

Frederick M. Lowery, vice-président exécutif de Thermo Fisher Scientific (TMO), a réalisé plusieurs cessions d'actions ordinaires le 28/08/2025 au prix de 489,74 USD par action. Le formulaire 4 indique quatre écritures de cession distinctes totalisant 667,718 actions cédées (175,028 + 187,116 + 186,632 + 118,942) et la détention directe restante signalée en montants fractionnaires (14,860.0624; 14,672.9464; 14,486.3144; 14,367.3724 selon les lignes). Le dépôt signale également des participations indirectes de 1,174.88 actions via un plan 401(k) et de 5.036 actions via une société à responsabilité limitée, avec une déclinaison de propriété bénéficiaire pour la position détenue par la LLC.

Frederick M. Lowery, Executive Vice President von Thermo Fisher Scientific (TMO), meldete mehrere Veräußerungen von Stammaktien am 28.08.2025 zu einem Kurs von 489,74 USD je Aktie. Das Formular 4 weist vier separate Veräußerungsposten aus, die insgesamt 667,718 veräußerte Aktien ergeben (175,028 + 187,116 + 186,632 + 118,942), und den verbleibenden direkten Besitz in Bruchteilen (14,860.0624; 14,672.9464; 14,486.3144; 14,367.3724 in den jeweiligen Zeilen). Die Meldung nennt außerdem indirekte Beteiligungen von 1,174.88 Aktien über einen 401(k)-Plan und 5.036 Aktien über eine Limited Liability Company, wobei für die LLC-Position das wirtschaftliche Eigentum verneint wird.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lowery Frederick M.

(Last) (First) (Middle)
168 THIRD AVENUE

(Street)
WALTHAM MA 02451

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
THERMO FISHER SCIENTIFIC INC. [ TMO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Executive Vice President
3. Date of Earliest Transaction (Month/Day/Year)
08/28/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/28/2025 F 175.028 D $489.74 14,860.0624 D
Common Stock 08/28/2025 F 187.116 D $489.74 14,672.9464 D
Common Stock 08/28/2025 F 186.632 D $489.74 14,486.3144 D
Common Stock 08/28/2025 F 118.942 D $489.74 14,367.3724 D
Common Stock 1,174.88(1) I by 401K
Common Stock 5.036 I by Limited Liability Company(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Between February 29, 2025 and August 28, 2025, the reporting person acquired 27.08 shares of TMO common stock under the TMO 401(k) plan.
2. The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
/s/ Melodie T. Morin, Attorney-in-Fact for Frederick M. Lowery 09/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Frederick M. Lowery report on the Form 4 for TMO?

The Form 4 reports four dispositions of Thermo Fisher Scientific common stock on 08/28/2025 at $489.74 per share and shows remaining direct and indirect holdings.

How many shares were disposed by the insider on 08/28/2025?

The filing shows dispositions of 175.028, 187.116, 186.632, and 118.942 shares, totaling 667.718 shares.

Does the Form 4 show any indirect holdings for the reporting person?

Yes. The report lists 1,174.88 shares held via a TMO 401(k) plan and 5.036 shares indirectly held by a limited liability company, with a disclaimer of beneficial ownership for the LLC position.

What is the reporting person's role at Thermo Fisher Scientific?

The filing identifies the reporting person as an Executive Vice President of Thermo Fisher Scientific.

Was this Form 4 filed jointly by multiple reporting persons?

No. The form indicates it was filed by one reporting person.
Thermo Fishr Sci

NYSE:TMO

TMO Rankings

TMO Latest News

TMO Latest SEC Filings

TMO Stock Data

186.06B
376.94M
0.16%
91.85%
0.98%
Diagnostics & Research
Measuring & Controlling Devices, Nec
Link
United States
WALTHAM